TTRX

Turn Therapeutics Inc.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0002023016 Biotech & Drug Discovery

$10.61 +0.33 (+3.21%)

Oct 26 4:00 PM ET · prev $10.28

Market cap

$310.8M

Small cap

Consensus

Buy

78% Buy or better · 9 analysts

Median target

$25.00

+136% · range $24.00–26.00

Next earnings

Nov 12

in 16 days · EPS est. −$0.09

1 year

+113.5%

from $4.97 · Oct 27

30 days

−18.6%

from $13.04

52-week range

$2.71–15.34

−31% from high · low Nov 20

Avg volume 20D

93.8K

shares / day

Short interest

🔒 Subscribers only

Insider net

no open-market trades · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 5 reports · 90 days

Balance 0 bearish · 1 bullish · 4 neutral oldest → newest, height = score

Avg score

·High conf. 4/5 ·Next Earnings date, Nov 12, 2026

Strongest NEUTRAL Turn Therapeutics released an updated investor presentation on October 6, 2026, detailing progress across…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Apr 3 Turn Therapeutics has two effective registration statements (File No…
R Jun 1 Turn Therapeutics reported positive interim Phase 2 data for GX-03 i…
R Jun 3 Turn Therapeutics released an updated investor presentation at the J…
R Jul 7 Turn Therapeutics announced the completion of a comprehensive interi…
X Jul 31 Short interest jumps 46.1% to 84.3K
X Aug 14 Short interest jumps 36.2% to 114.8K
X Sep 30 Short interest jumps 74.1% to 268.8K
A Oct 23 WBB Securities upgrades

Signal stack

Where each data set points today.

InsidersNO TRADES

No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
InstitutionsMIXED

Q2 2026: 2 added (0 new), 0 trimmed or exited.
AnalystsBULLISH

7 of 9 rate it Buy or better. Every target is above the price.
TrendDOWNTREND

9% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
VANGUARD CAPITAL MANAGEMENT LLC	ADD	74,301	$542.4K
UBS Group AG	DOUBLED	2,263	$16.5K
MILLENNIUM MANAGEMENT LLC	TRIM	69,757	$223.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts

Buy 78% rate it Buy or better

Strong Buy3Buy4Hold1Sell1Strong Sell0

12-month targets · 2 analysts

$10.61 $24.00 $25.00 $26.00

Price is below the lowest target. Median implies +136%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Oct 23, 2026	WBB Securities UPGRADE	UPGRADE	Hold
Sep 24, 2026	LUCID CAPITAL MARKETS INITIATE	INITIATE	Buy
Sep 14, 2026	WBB Securities DOWNGRADE	DOWNGRADE	Sell

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Upcoming

Nov 12, 2026

Earnings date

TTRX Q3 2026 Earnings Scheduled — 2026-11-12

Recent

Aug 10, 2026

Earnings date

TTRX Q2 2026 Earnings Scheduled — 2026-08-10

Jul 6, 2026

Earnings date

TTRX Q2 2026 Earnings Scheduled — 2026-07-06

Jun 25, 2026

Earnings date

TTRX Q2 2026 Earnings Scheduled — 2026-06-25

Insider ledger

Form 4

open-market buys or sells · 12 mo

Date	Insider	Type	Value
Jun 4, 2026	Kester Kent Edward Director	AWARD	83,334 sh
Jun 4, 2026	Dewhurst Martin William Director	AWARD	71,666 sh
Jun 4, 2026	GOLDEN ARTHUR F Director	AWARD	89,584 sh
Jun 4, 2026	Gengos Andrew Director	AWARD	95,000 sh
May 28, 2026	Burnam Bradley Evan Chief Executive Officer	GIFT	300,000 sh
Apr 2, 2026	GOLDEN ARTHUR F Director	GIFT	300,000 sh
Apr 2, 2026	Burnam Bradley Evan Chief Executive Officer	GIFT	300,000 sh
Apr 1, 2026	Chaudhary Zuraiz See Remarks	AWARD	80,000 sh

Earnings setup

Estimates

Nov 12

reports in 16 days

−$0.09

EPS estimate, this quarter

Current-quarter EPS estimate

$0.000

90d

−$0.030

60d

−$0.090

30d

−$0.090

−$0.085

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.09	-$0.09–-$0.08	+5.6%	$0.00
Next Q	-$0.14	-$0.20–-$0.08	-75.0%	$0.00
Current FY	-$0.46	-$0.52–-$0.40	-15.0%	$250.0K
Next FY	-$0.45	-$0.51–-$0.39	-15.4%	$2.5M